Flai (fludarabine, cytarabine, idarubicin) plus low ‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial
American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Source Type: research
More News: Clinical Trials | Hematology